Brian Evanko to be Cigna CEO starting in July

Brian Evanko will become CEO of The Cigna Group after current CEO David M. Cordani, who was in the role for nearly 17 years, retires on July 1, 2026.

Evanko has been with Cigna for more than 25 years and currently is president and chief operating officer. For the last year, he has overseen Cigna Healthcare and Evernorth Health Services. Previously, he served as the company’s chief financial officer, and over his time at Cigna, he has held commercial and functional leadership roles.

“I’m really excited about the opportunity to lead The Cigna Group in the next chapter, using the power of data, advanced analytics, and insights to give people care that’s more relevant in their health care journey, and our Lead to One strategy is a great example of the investments we’re making to be more customer- and patient-first on a go-forward basis,” Evanko said in a video on the company’s website.

Cordani will join the company’s board of directors as executive chair. He has overseen the company as it transitioned from a traditional insurer generating $18 billion in annual revenue to an integrated healthcare services company with annual revenue of $275 billion. During his tenure, Cigna acquired the PBM Express Scripts and launched Evernorth Health Services, a division of the company that provides pharmacy, care and benefits. Evernorth’s businesses include the specialty pharmacy Accredo, the virtual care company MDLive and eviCore, which manages prior authorizations and utilization review services.

Over the next 100 days, Cordani said he will be working with Evanko to ensure a seamless transition. “As we look forward, we’re heading into another transitional chapter; for that next chapter, I’m confident that Brian is our next leader,” Cordani said.

Evanko said his focus for Cigna will be to use data, technology and AI across the company’s business, as well as to provide more personalized healthcare. “I am excited to build on our strong foundation as we work to further modernize health care, expand our reach, and fuel growth,” Evanko said in the news release.

Additionally, Cigna has affirmed its projected full-year 2026 consolidated adjusted income from operations of at least $30.25 per share, which was announced in February 2026 during a call with investors.

Related: 3 takeaways from Cigna’s 2025 earnings call

For the full year 2025, the company saw total revenue increase 11% to $274.9 billion compared with 2024. Adjusted earnings per share were $29.84 for 2025, representing 9% growth. Express Scripts, which sits within the Cigna’s Evernorth division, saw adjusted 2025 revenue grow by 18%, which executives said was the result of growth from existing clients and new business.

Also in February, the company settled a lawsuit brought by the Federal Trade Commission. Express Scripts agreed to make big changes in how it operates, including reimbursing community pharmacists based on actual costs, increasing transparency for plan sponsors and making sure members pay the lowest available cost for medication. The settlement will also require that its group purchasing organization, Ascent, be relocated within the United States instead of Switzerland.

Cigna executives said during the 2025 earnings call that these changes could impact the company’s effective tax rate by up to 1% over time. During the question-and-answer session with analysts, the company said this was manageable against the company’s long-term earnings growth expectation of 10% to 14%.

The FTC had sued Express Scripts, as well as CVS Caremark and Optum Rx, in September 2024, saying the PBMs and their group purchasing organizations inflated the list price of drugs, including insulin, and shifted costs to patients.